Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

NCT07010393 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

335

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Neoplasms

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Selpercatinib
DRUG: Pralsetinib
DRUG: Lenvatinib
DRUG: Larotrectinib
DRUG: Anlotinib
DRUG: Pembrolizumab
DRUG: Sintilimab
DRUG: Cabozantinib
DRUG: Bemosuzumab
PROCEDURE: Conversion Surgery

Sponsor

Fujian Medical University